Shares of OvaScience Inc (NASDAQ:OVAS) were up 3.1% on Monday . The company traded as high as $5.80 and last traded at $5.72, with a volume of 59,117 shares trading hands. The stock had previously closed at $5.55.

A number of analysts have weighed in on OVAS shares. Zacks Investment Research upgraded OvaScience from a “hold” rating to a “buy” rating and set a $7.00 price target on the stock in a research report on Wednesday, August 10th. Leerink Swann reiterated a “hold” rating and issued a $7.00 price target (up from $6.00) on shares of OvaScience in a research report on Sunday, May 8th. JMP Securities reiterated a “neutral” rating on shares of OvaScience in a research report on Wednesday, August 10th. JPMorgan Chase & Co. lowered their price target on OvaScience from $9.00 to $8.00 and set a “neutral” rating on the stock in a research report on Friday, August 5th. Finally, Credit Suisse Group AG reiterated a “sell” rating on shares of OvaScience in a research report on Tuesday, July 12th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and three have given a buy rating to the company. OvaScience currently has a consensus rating of “Hold” and a consensus price target of $10.98.

The firm’s market cap is $210.17 million. The company has a 50-day moving average price of $5.64 and a 200-day moving average price of $7.07.

OvaScience (NASDAQ:OVAS) last issued its quarterly earnings results on Thursday, August 4th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.78) by $0.16. During the same quarter in the previous year, the business posted ($0.64) EPS. The business earned $0.19 million during the quarter, compared to the consensus estimate of $0.21 million. The company’s revenue for the quarter was up 530.0% on a year-over-year basis. On average, equities research analysts expect that OvaScience Inc will post ($2.66) EPS for the current year.

In other OvaScience news, CEO Michelle Dipp purchased 425,000 shares of the firm’s stock in a transaction dated Wednesday, June 1st. The shares were bought at an average price of $7.00 per share, for a total transaction of $2,975,000.00. Following the purchase, the chief executive officer now owns 971,921 shares in the company, valued at approximately $6,803,447. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.